Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersPharmacotherapy augmentation strategies in treatment-resistant anxiety disordersQuetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]Off-label indications for atypical antipsychotics: A systematic reviewThe role of atypical antipsychotics in bipolar depression and anxiety disordersSynergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review.Breast enlargement associated with low dose olanzapineAripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study.Current management of obsessive and phobic states.Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder.Antipsychotic treatment in obsessive-compulsive disorder: a literature review.A review of antipsychotics in the treatment of obsessive compulsive disorder.Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.Symptom subtypes of obsessive-compulsive disorder: are they relevant for treatment?Treatment strategies for obsessive-compulsive disorder.Pharmacological management of treatment-resistant obsessive-compulsive disorder.Augmentation strategies in obsessive-compulsive disorder.DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria.Schizo-obsessive spectrum disorders: an update.Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine.The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.The clinical characteristics of obsessive compulsive disorder associated with high levels of schizotypy.A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case seriesCritical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders
P2860
Q22305681-3C9B44DE-5C99-41C5-A829-7F28D33B500EQ24243827-1861CC3D-E1A5-49F0-91E6-589309A4F00AQ24798724-CEB98DB9-CC53-4FA0-B94B-08AC0E47A892Q24803302-D841E994-5BBC-469F-B9AA-DE7E6E1C92A7Q28236713-F63EEE73-40BD-4A16-B729-8ADB5D49E3C8Q34177643-734046A3-ABCC-4803-8258-C866CDD6ED4AQ34681173-239A4D68-5AC6-487F-868E-BA9173E3C60DQ34706526-D894ACF6-8FD2-4868-8641-9395B33128F8Q35047082-A63C3FC6-2D60-4EA2-860B-D68FAED4B438Q35327098-14068982-4430-4F82-8D1B-1F4B35744966Q35906894-391AA649-7208-4602-8F67-3710AF3618F9Q36110049-D1A6F63E-F839-4885-9CC7-B2045DB2DB5DQ36276544-62E4FF16-4ABC-4260-A6D5-1386D15000F5Q36326268-B5074EE2-5C16-4ABC-9F38-964773951471Q37214734-774C4F42-EB98-4F2D-9534-BD76E080C781Q37681560-EC258C7E-EE38-499D-ABEB-111A1A2EB13EQ37893636-09F5D0C4-C2A7-4C14-BEC2-8A18DE0E086AQ38078029-41287F78-F377-4F64-B8F0-D579810A8343Q38194998-449BD917-06A7-4A3B-9B70-0079AB572F4CQ38964747-89A099C9-B77E-42A6-BCF8-FF2718F03F53Q41732393-432754B6-CF14-48D7-90CE-24A8753383C0Q44938175-B3F0C677-DB61-4047-8E3B-B25A01A489D7Q48311962-AB2F0FA7-E88C-4645-8C5D-7739FDAE89C0Q56909919-AE853EAF-AAC8-411B-AF92-87427CD72211Q58780376-75BA4C22-0800-4913-9E5F-F10705929F44
P2860
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Olanzapine augmentation of flu ...... r (OCD): a 12-week open trial.
@en
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder
@nl
type
label
Olanzapine augmentation of flu ...... r (OCD): a 12-week open trial.
@en
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder
@nl
prefLabel
Olanzapine augmentation of flu ...... r (OCD): a 12-week open trial.
@en
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder
@nl
P2093
P1433
P1476
Olanzapine augmentation of flu ...... r (OCD): a 12-week open trial.
@en
P2093
P356
10.1016/S0165-1781(00)00203-1
P407
P577
2000-10-01T00:00:00Z